{"id":173653,"date":"2026-01-22T10:26:59","date_gmt":"2026-01-22T15:26:59","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=173653"},"modified":"2026-01-22T10:27:01","modified_gmt":"2026-01-22T15:27:01","slug":"syngene-q3-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/syngene-q3-fy26-earnings-results\/","title":{"rendered":"Syngene Q3 FY26 Earnings Results"},"content":{"rendered":"\n<p>Syngene (established in 1993) as a Biocon subsidiary is India&#8217;s first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research &amp; manufacturing infrastructure for the company is spread across 1.9 million square feet across locations.<\/p>\n\n\n\n<div style=\"height:32px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\">Q3 FY26 Earnings Results (Standalone)<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Revenue from Operations: \u20b9834.4 crore, down 4.9% YoY from \u20b9877.1 crore in Q3 FY25; flat QoQ vs Q2 FY26.<\/li>\n\n\n\n<li>Total Income: \u20b9848.9 crore, down 5.2% YoY from \u20b9895.1 crore.<\/li>\n\n\n\n<li>Total Expenses: \u20b9753.0 crore, down ~1% YoY.\u200b<\/li>\n\n\n\n<li>Profit Before Tax (PBT): \u20b995.9 crore, down 43.5% YoY from \u20b9169.8 crore.<\/li>\n\n\n\n<li>Exceptional Charges: \u20b965.8 crore related to new Labour Code regulations.<\/li>\n\n\n\n<li>Profit After Tax (PAT): \u20b916.5 crore, down 86.6% YoY from \u20b9123.1 crore.<\/li>\n\n\n\n<li>Basic EPS: \u20b90.41 vs \u20b93.07 in Q3 FY25.<\/li>\n\n\n\n<li>9M FY26:\n<ul class=\"wp-block-list\">\n<li>Revenue from Operations: \u20b92,463.8 crore, up 1.6% YoY from \u20b92,424.9 crore.<\/li>\n\n\n\n<li>PAT: \u20b9156.7 crore, down 46.6% YoY from \u20b9293.6 crore.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Q3 FY26 Earnings Results (Consolidated)<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Revenue from Operations: \u20b9917.1 crore, down 2.8% YoY from \u20b9943.7 crore.<\/li>\n\n\n\n<li>Reported EBITDA: \u20b9225 crore, down 26% YoY.\u200b<\/li>\n\n\n\n<li>Reported EBITDA Margin: 24%.\u200b<\/li>\n\n\n\n<li>Reported PAT (before exceptional items): \u20b973 crore, down 44% YoY.\u200b<\/li>\n\n\n\n<li>Reported PAT Margin: 8%.\u200b<\/li>\n\n\n\n<li>Reported PAT: \u20b915 crore, down 88.5% YoY from \u20b9131 crore.\u200b<\/li>\n\n\n\n<li>9M FY26:\n<ul class=\"wp-block-list\">\n<li>Revenue: \u20b92,702 crore, up 3% YoY.\u200b<\/li>\n\n\n\n<li>Reported PAT: ~\u20b9168.8 crore (implied from H1 data), down significantly YoY.\u200b<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<div style=\"height:32px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\">Management Commentary &amp; Strategic Decisions<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Management attributed Q3 profit decline to one\u2011time Labour Code costs and single\u2011product impact in biologics manufacturing; <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/522207fc-02a6-4b67-bf22-141dabe09183.pdf\" target=\"_blank\" rel=\"noopener\">underlying business remains resilient<\/a> with revenue growth from research services offsetting inventory corrections. Extended partnership with Bristol Myers Squibb to 2035, strengthening long\u2011term revenue visibility in discovery and development services.\u200b<\/li>\n\n\n\n<li>Major investments in biologics capacity and strategic shifts to higher\u2011margin services continue despite near\u2011term profitability pressures.<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"839\" height=\"1024\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Syngene-Q3-FY26-Earnings-Results-839x1024.png\" alt=\"\" class=\"wp-image-173679\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Syngene-Q3-FY26-Earnings-Results-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Syngene-Q3-FY26-Earnings-Results-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Syngene-Q3-FY26-Earnings-Results-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Syngene-Q3-FY26-Earnings-Results-1259x1536.png 1259w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Syngene-Q3-FY26-Earnings-Results.png 1489w\" sizes=\"auto, (max-width: 839px) 100vw, 839px\" \/><\/figure>\n\n\n\n<div style=\"height:35px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\">Q2 FY26 Earnings Results (Standalone)<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Revenue from Operations: \u20b9911 crore, up 2% YoY from \u20b9908 crore; up 4% QoQ.<\/li>\n\n\n\n<li>Reported EBITDA: \u20b9215 crore, down 18% YoY from \u20b9262 crore; EBITDA margin 23.2% vs 28.8% YoY.<\/li>\n\n\n\n<li>Reported PAT: \u20b967 crore, down 37% YoY from \u20b9106 crore.<\/li>\n\n\n\n<li>H1 FY26: Revenue from Operations up 6% YoY.\u200b<\/li>\n<\/ul>\n\n\n\n<div style=\"height:32px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\">Management Commentary &amp; Strategic Directions \u2013 Q2 FY26<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Q2 performance driven by research services growth offsetting biologics inventory correction; maintaining FY26 revenue guidance with focus on capacity utilisation and margin recovery.<\/li>\n<\/ul>\n\n\n\n<p>To view the company\u2019s previous earnings and latest concall transcripts,&nbsp;<a href=\"https:\/\/alphastreet.com\/india\/\">click here<\/a>&nbsp; to visit the Alphastreet India news channel.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Syngene (established in 1993) as a Biocon subsidiary is India&#8217;s first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research &amp; manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. Q3 [&hellip;]<\/p>\n","protected":false},"author":1863,"featured_media":173679,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,5747],"tags":[1115],"class_list":["post-173653","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-healthcare-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Syngene-Q3-FY26-Earnings-Results.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":172182,"url":"https:\/\/alphastreet.com\/india\/syngene-q2-fy26-earnings-results\/","url_meta":{"origin":173653,"position":0},"title":"Syngene Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 6, 2025","format":false,"excerpt":"Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Syngene Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Syngene-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170228,"url":"https:\/\/alphastreet.com\/india\/syngene-q1-fy26-earnings-results\/","url_meta":{"origin":173653,"position":1},"title":"Syngene Q1 FY26 Earnings Results","author":"Chirag Gupta","date":"August 15, 2025","format":false,"excerpt":"Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Syngene Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-10.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":177373,"url":"https:\/\/alphastreet.com\/india\/syngene-international-reports-marginal-revenue-growth-and-sharp-profit-decline-in-q3-fy26-results\/","url_meta":{"origin":173653,"position":2},"title":"Syngene International reports marginal revenue growth and sharp profit decline in Q3 FY26 results","author":"Staff Correspondent","date":"January 23, 2026","format":false,"excerpt":"Current Status Overview Syngene International Ltd is an India-based contract research, development, and manufacturing services company serving pharmaceutical and biotechnology clients. The company reported muted revenue growth and significant profit contraction in its most recent quarterly results. Share Price Performance The company\u2019s shares were trading around INR 545\u2013558 on the\u2026","rel":"","context":"In &quot;Analysis&quot;","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":173275,"url":"https:\/\/alphastreet.com\/india\/rajratan-global-wire-q3-fy26-earnings-results\/","url_meta":{"origin":173653,"position":3},"title":"Rajratan Global Wire Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"January 22, 2026","format":false,"excerpt":"The Company is engaged in the manufacturing of bead wire, a high-carbon steel wire utilized in the production of tires. Additionally, the Company produces drawn steel wire, commonly referred to as black wire, which finds applications in various industries such as automobile, construction, and engineering.\u00a0 Q3 FY26 Earnings Results Revenue\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Rajratan-Global-Wires-Q3-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Rajratan-Global-Wires-Q3-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Rajratan-Global-Wires-Q3-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Rajratan-Global-Wires-Q3-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Rajratan-Global-Wires-Q3-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Rajratan-Global-Wires-Q3-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":180581,"url":"https:\/\/alphastreet.com\/india\/biocon-posts-9-operating-revenue-growth-in-q3-fy26-ebitda-margin-at-22\/","url_meta":{"origin":173653,"position":4},"title":"Biocon posts 9% operating revenue growth in Q3 FY26; EBITDA margin at 22%","author":"Staff Correspondent","date":"February 13, 2026","format":false,"excerpt":"Biocon Limited (BSE: 532523 \/ NSE: BIOCON) reported consolidated operating revenue growth of 9% year-on-year for the quarter ended December 31, 2025, supported by gains in its biosimilars and generics businesses. Operating revenue for Q3 FY26 stood at \u20b94,173 crore compared with \u20b93,821 crore in Q3 FY25. Total revenue increased\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":173235,"url":"https:\/\/alphastreet.com\/india\/wendt-q3-fy26-earnings-results\/","url_meta":{"origin":173653,"position":5},"title":"Wendt Q3 FY26 Earnings Results","author":"Chirag Gupta","date":"January 21, 2026","format":false,"excerpt":"Wendt India is a leading manufacturer of Super Abrasives, Machining Tools, and Precision Components. It is a preferred supplier for many of the automobile, auto component, engineering, aerospace, defense ceramics customers for their Super Abrasive Tooling solutions, Grinding & Honing Machines, and Precision components. Q3 FY26 Earnings Results Revenue from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Wendt-Q3-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Wendt-Q3-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Wendt-Q3-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Wendt-Q3-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Wendt-Q3-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/Wendt-Q3-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/173653","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1863"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=173653"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/173653\/revisions"}],"predecessor-version":[{"id":173758,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/173653\/revisions\/173758"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/173679"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=173653"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=173653"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=173653"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}